SEAL uses a patented aerosol delivery system to disperse dry chitosan particles at high velocity. This approach allows the material to reach irregular wound surfaces and complex geometries that are difficult to treat with dressings, gauze, or loose powders. Upon contact with blood, the aerosolized particles begin forming a cohesive barrier when combined with pressure.

The aerosol system is designed for predictable dispersion and uniform coverage across the wound surface. The OTC can is ~65 PSI, and the Pro can is ~80 PSI. Performance remains stable across real-world handling, transport, and storage conditions, ensuring reliable deployment in environments where access, visibility, and time are limited.

SEAL is designed to function when bleeding control is most challenging. In arterial bleeding models, including subjects with impaired clotting due to anticoagulation, SEAL achieved rapid and sustained hemorrhage control by forming a physical barrier independent of normal coagulation pathways.

SEAL has completed environmental and altitude testing aligned with MIL-STD-810H protocols. The product maintained aerosol performance and hemostatic function following exposure to temperatures ranging from −31°C (−24°F) to 71°C (160°F), as well as altitude testing up to 40,000 feet, without degradation or loss of effectiveness.

SEAL is designed to integrate directly into existing bleeding control protocols without adding complexity. The aerosol format enables rapid application in prehospital and emergency settings, while remaining fully compatible with standard trauma workflows once a patient transitions to definitive care. No mixing, assembly, or specialized equipment is required.

SEAL forms a temporary hemostatic barrier that does not permanently bond to tissue. For medical professionals, removal is straightforward and non-traumatic, requiring only saline or sterile water and gauze. The formulation is non-exothermic and does not cause secondary tissue damage when used as indicated, allowing subsequent medical or surgical treatment to proceed without complication.

SEAL is supported by laboratory testing and preclinical evaluation designed to reflect real-world trauma and emergency use. Completed testing includes arterial hemorrhage models assessing rapid bleeding control, including scenarios where clotting function is intentionally impaired. These evaluations inform both product design and clinical positioning.

In addition to completed studies, SEAL continues to undergo structured evaluation to expand indications and validate performance across environments. This includes environmental and altitude qualification aligned with military standards, as well as ongoing and planned research programs focused on burn wounds, long-term tissue response, and controlled clinical use cases in collaboration with academic medical partners.